Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company distributes and sells plant-based pharmaceutical products.
| Line item | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|
| 3,463 | 4,794 | 5,362 | +24.4% | |
| Total COGS | 0 | 0 | 0 | |
| Gross Profit | 3,463 | 4,794 | 5,362 | +24.4% |
| Gross Margin | 100.0% | 100.0% | 100.0% | |
| 4,037 | 4,455 | 4,251 | +2.6% | |
| EBITDA | 574 | 338 | 1,112 | nmf |
| EBITDA Margin | 16.6% | 7.1% | 20.7% | |
| Total D&A | 27 | 37 | 47 | +31.0% |
| EBIT / Operating Income | 602 | 301 | 1,065 | nmf |
| Total Interest Income | 111 | 59 | 242 | +47.7% |
| Total Interest Expense | 221 | 91 | 130 | -23.3% |
| Total Other Income | 0 | 0 | 89 | |
| Profit Before Tax | 711 | 270 | 1,265 | nmf |
| Total Income Tax | 0 | 0 | 0 | |
| Net Profit / (Loss) | 711 | 270 | 1,265 | nmf |
| Net Margin | 20.5% | 5.6% | 23.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →